Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
Joshua Ruch (2)(4) 72 Director Rachel Sherman, M.D., M.P.H., F.A.C.P. (3)(6) 64 Director __________________ (1) Chair of the Audit Committee (2) Chair of the Compensation Committee (3) Chair of the Nominating and Corporate Governance Committee (4) Member of the Nominating and Corporate Governance Committee (5) Member of the Audit Committee (6) Member of the Compensation Committee Executive Officers Katherine Stueland has served as our Chief Executive Officer and as a member of our Board since April 2022. Previously, Ms. Stueland served as the President and Chief Executive Officer of GeneDx from June 2021 to the closing of the Acquisition. Prior to joining GeneDx, Ms. Stueland served as the Chief Commercial Officer at Invitae Corporation, a biotechnology company, from October 2016 to June 2021 and as the Head of Communications and Investor Relations at Invitae Corporation from November 2013 to October 2016, during which time she helped Invitae Corporation transition from a private to a public company. Ms.
This record is keyed to SEC CIK 0000943431 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 232 institutional-holder rows on these vehicles, under 66 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.